Lymphoma Patients Show Continued Cognitive Decline After Chemotherapy
Lymphoma patients displayed cognitive decline 6 months after chemotherapy, both by objective assessment and self-report.
Lymphoma
LYMPHOMA ADVISOR
FEATURED CONTENT
-
-
How to Manage Venetoclax Resistance in Chronic Lymphocytic Leukemia
Experts outline treatment options for patients with venetoclax resistance. -
Underdosing in Patients With Cancer and Obesity: A Thing of the Past?
New guidelines recommend using the full approved doses of immunotherapy and targeted therapies for patients with cancer and obesity. -
COVID-19 Vaccination and Imaging Misinterpretation: An Interview With Lacey McIntosh, DO, MPH
Oncologists and patients should be aware of the potential manifestations of the COVID-19 vaccination on imaging and the consequences this might have on disease assessment, treatment monitoring, and decision-making. -
Data From the CAPTIVATE Study’s uMRD Cohort Suggest Role for Fixed-Duration Therapy in CLL/SLL [Q&A]
John N. Allan, MD, a lead author of the CAPTIVATE study, discusses the findings from the uMRD cohort and their implications for the CLL/SLL paradigm.
LYMPHOMA NEWS
Low Rate of Cardiac Toxicity Reported With Acalabrutinib in CLL
Acalabrutinib, Venetoclax, Obinutuzumab Shows Promise as Frontline Therapy for Chronic Lymphocytic Leukemia
MRD Assessment Can Guide Treatment Discontinuation in CLL/SLL
Trial Comparing Pirtobrutinib With Bendamustine Plus Rituximab in CLL/SLL
Tafasitamab Plus Lenalidomide and Rituximab for Follicular Lymphoma and Marginal Zone Lymphoma
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in Lymphoma
Loading... 
Loading...